D. Boral Capital Cuts Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target to $2.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective dropped by D. Boral Capital from $3.00 to $2.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. D. Boral Capital’s price target would indicate a potential upside of 204.88% from the company’s current price.

A number of other equities research analysts have also recently commented on LCTX. Maxim Group decreased their target price on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Friday, January 31st.

Lineage Cell Therapeutics Stock Down 2.1 %

NYSEAMERICAN:LCTX opened at $0.66 on Tuesday. The company has a market capitalization of $144.60 million, a price-to-earnings ratio of -5.47 and a beta of 1.21. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of LCTX. SG Americas Securities LLC bought a new stake in Lineage Cell Therapeutics in the third quarter worth $46,000. Fort Sheridan Advisors LLC increased its holdings in shares of Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares during the last quarter. Atria Wealth Solutions Inc. purchased a new stake in shares of Lineage Cell Therapeutics during the 4th quarter valued at about $29,000. HighTower Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 49.5% in the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after acquiring an additional 19,100 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Lineage Cell Therapeutics in the third quarter worth about $84,000. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.